Wesley H Self, Mark W Tenforde, Jillian P Rhoads, Manjusha Gaglani, Adit A Ginde, David J Douin, Samantha M Olson, H Keipp Talbot, Jonathan D Casey, Nicholas M Mohr, Anne Zepeski, Tresa McNeal, Shekhar Ghamande, Kevin W Gibbs, D Clark Files, David N Hager, Arber Shehu, Matthew E Prekker, Heidi L Erickson, Michelle N Gong, Amira Mohamed, Daniel J Henning, Jay S Steingrub, Ithan D Peltan, Samuel M Brown, Emily T Martin, Arnold S Monto, Akram Khan, Catherine L Hough, Laurence W Busse, Caitlin C Ten Lohuis, Abhijit Duggal, Jennifer G Wilson, Alexandra June Gordon, Nida Qadir, Steven Y Chang, Christopher Mallow, Carolina Rivas, Hilary M Babcock, Jennie H Kwon, Matthew C Exline, Natasha Halasa, James D Chappell, Adam S Lauring, Carlos G Grijalva, Todd W Rice, Ian D Jones, William B Stubblefield, Adrienne Baughman, Kelsey N Womack, Christopher J Lindsell, Kimberly W Hart, Yuwei Zhu, Lisa Mills, Sandra N Lester, Megan M Stumpf, Eric A Naioti, Miwako Kobayashi, Jennifer R Verani, Natalie J Thornburg, Manish M Patel
Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged ≥18 years and aged ≥16 years, respectively. A 1-dose viral vector vaccine (Ad26.COV2 from Janssen [Johnson & Johnson]) received EUA in February 2021 for persons aged ≥18 years (3). The Pfizer-BioNTech vaccine received FDA approval for persons aged ≥16 years on August 23, 2021 (4)...
September 24, 2021: MMWR. Morbidity and Mortality Weekly Report